A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia/lymphoma

Conclusion Mogamulizumab improves OS in ATL, although its use in HSCT patients might trigger severe GVHD. Determining the optimal pre-HSCT mogamulizumab treatment regimen is thus a priority. Teaser Mogamulizumab recently became available for the treatment of adult T-cell leukemia/lymphoma (ATL). We conducted a multicenter retrospective study of the efficacy of mogamulizumab in ATL treatment in patients in Japan, and found that mogamulizumab is an effective therapeutic strategy in ATL. There is some concern that the use of mogamulizumab in hematopoietic stem cell transplantation patients might cause severe GVHD. Determining the optimum number of mogamulizumab administrations should be a priority for future studies.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research